Drug Trial Radar · NCT04643587
Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Dec 7, 2020
Primary completion
Mar 12, 2023
Study completion Mar 12, 2023
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.
Conditions
- Noncystic Fibrosis Bronchiectasis (NCFB)
Interventions
CSL787Biological
Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
PlaceboDrug
Normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with treatment emergent adverse events (TEAEs) - overall, severity and causalityTime frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)
- Percent of subjects with TEAEs - overall, severity and causalityTime frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
IKF Pneumologie Institute
Frankfurt, Germany
Medicines Evaluation Unit (MEU)
Manchester, England, United Kingdom
Celerion
Belfast, Northern Ireland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.